SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is surging following a blowout earnings report where significant Azure growth and strong guidance successfully countered recent market anxiety regarding AI infrastructure costs. Community sentiment has shifted dramatically, with investors celebrating the stock's role in stabilizing the broader market while shorts face intense pressure amid a heavy wave of bullish commentary and price target upgrades.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing extreme volatility as investors weigh the ongoing surge in AI infrastructure demand against macro-economic fears and recent hedge fund liquidations. The community is sharply divided between bulls focused on the long-term potential of AI hyperscale cloud capacity and bears who are increasingly concerned about the sustainability of current valuations and potential margin pressure.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is currently the subject of intense community debate as investors navigate a disconnect between the company's strong operational performance, evidenced by record ABS issuance, and its stagnant, often volatile stock price. While supporters highlight institutional confidence and analyst buy ratings as potential catalysts for a major breakout, skeptics remain focused on the impact of macro headwinds and persistent institutional selling pressure.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh a strong earnings performance against broader market pessimism toward AI infrastructure and high-beta assets. The community remains deeply divided, with many long-term bulls viewing the dip as a prime accumulation opportunity while others express frustration over the disconnect between the company's contracted backlog and its recent price action.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending as investors weigh a standout earnings report featuring record revenue and raised guidance against broader market volatility and institutional sell-side pressure. The community is sharply divided, with bulls pointing to the company's critical role in powering AI data centers, while others remain cautious due to sector-wide weakness and recent sharp price fluctuations.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened community discussion surrounding an upcoming maintenance dosing data readout and anticipation for its Q2 earnings call. Investors are focused on the company's clinical pipeline progress, with many debating the implications of a recent board appointment and ongoing volatility driven by speculation regarding potential M&A activity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's broad regulatory approval of ANKTIVA for both bladder and lung cancer, an expansion that bolsters its global footprint and fuels community speculation regarding international revenue potential. Investors are closely monitoring this momentum as they weigh the company's international commercial progress against upcoming quarterly earnings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing extreme volatility as investors weigh aggressive AI capital expenditure news against signs of sector-wide capitulation. The community remains deeply divided, with many debating if recent lows represent a structural buying opportunity or a deeper correction fueled by margin calls and macroeconomic uncertainty.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to the release of its latest earnings report, which triggered sharp volatility as investors weighed a record-breaking quarter against full-year guidance that failed to meet lofty market expectations. The community remains deeply polarized, with active debates pitting bulls who point to sustained growth and operational execution against bears who continue to allege accounting irregularities and express skepticism regarding the company's subprime lending model.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is gaining momentum as investors focus on its path to operating profitability by the third quarter of 2026 and robust year-over-year revenue growth. The community is actively discussing the potential for a short squeeze given the high short interest, while also monitoring management's commercial strategy and the ongoing adoption of Voquezna as a standard-of-care gastrointestinal treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -100.00% and -84.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 42,883,635 shares, an increase of 14.0% from the March 31st total of 37,605,702 shares. Based on an average daily...

Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of...

Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction on Tuesday, April 21st. The stock was...

Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an...

Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday...

HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued...

Equities Analysts Issue Forecasts for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April...

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

Equity

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

$SGMO Q1 '26 Earnings Results & Recap

Sangamo Therapeutics expects GAAP total operating expenses to be approximately $110M to $130M in 2026, with non-GAAP expenses ranging from $100M to $120M, subject to securing adequate additional funding.

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGMOSangamo Therapeutics Inc

Fundamentals

Latest SGMO News